Antagonist clinical trials
How each study uses Antagonist is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Antagonist studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Antagonist
- 2
Studies by the year they started
5 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2012 | 1 |
| 2018 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Memorial Sloan Kettering Cancer Center (1) · Radiation Therapy Oncology Group (1) · Main Line Fertility Center (1) · Aljazeera Hospital (1) · Weill Medical College of Cornell University (1)
Often tested with
Tested in the same studies.
Abiraterone Acetate (1) · Abiraterone (1) · Prednisone (1) · Gonadotropin-releasing Hormone Analog (1) · Bicalutamide (1) · Flutamide (1) · Agonist (1) · Leuprolide (1)
Studies
Open first, then newest update. How each study uses Antagonist is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Ovarian Hyperstimulation Syndrome PreventionRecruitingNot applicableAljazeera HospitalNCT06739759Written as Antagonist protocol for IVF
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic AdenocarcinomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03436654Written as GnRH agonist/antagonist
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate CancerCompletedPhase 3Radiation Therapy Oncology GroupNCT00936390Written as LHRH agonist (antagonist) therapy
- Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of StimulationCompletedNot applicableMain Line Fertility CenterNCT01669291Written as Antagonist
- Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) PatientsWithdrawnPhase 4Weill Medical College of Cornell UniversityNCT00826839Written as E2 patch/antagonist
Given beside what is tested · 4 — Antagonist is usual care or a partner of the new treatment
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07783282Written as GnRH agonist/antagonist
- Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentTerminatedPhase 1Eli Lilly and CompanyNCT05999968Written as LHRH agonist/antagonist
- Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerActive, not recruitingPhase 4Northwestern UniversityNCT03016741Written as GnRH agonist/antagonist
- Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone MetastasesTerminatedPhase 2Ajjai Alva, MDNCT02582749Written as LHRH agonist/antagonist